Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a $35 price target on the stock.
December 20, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer has reaffirmed an Overweight rating on Longboard Pharmaceuticals with a steady price target of $35.
The reiteration of an Overweight rating and the maintenance of a $35 price target by a reputable analyst like Josh Schimmer could lead to increased investor confidence in LBPH, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100